Company Overview of Inhibitex, Inc.
Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections. It primarily focuses to treat shingles caused by the varicella zoster virus and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include INX-189, a HCV nucleoside polymerase inhibitor that has completed Phase Ib clinical trials for the treatment of chronic hepatitis C infection; FV-100, an orally available nucleoside analogue prodrug, which is in Phase II clinical trials for the treatment of herpes zoster or shingles. The company is also developing anti-bacterials comprising Staphylococcal Vaccines, wh...
9005 Westside Parkway
Alpharetta, GA 30009
Founded in 1994
Key Executives for Inhibitex, Inc.
Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer
Founder, Chief Scientific Officer, Senior Vice President of Research & Development and Assistant Secretary
Senior Vice President of Drug Development
Chief Medical Officer and Vice President of Clinical Development
Compensation as of Fiscal Year 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries